News

ivWatch Extends Its Global Reach Signing Three New Distribution Partners

Newport News, VA, ivWatch, LLC, an innovative IV safety company working to eliminate harm caused by infiltration and extravasation events, announced three new strategic distribution partnerships internationally. Bameco in Austria, Warba Medical Supplies in Kuwait, and Mustafa Sultan Science & Industry Co, LLC in Oman have each signed exclusive agreements to promote, sell, and support ivWatch’s continuous monitoring products in their markets. ivWatch’s novel technologies will complement and bolster their existing portfolios of intravenous products provided to hospitals and other health care facilities.

ivWatch solutions continue to be available in more countries throughout the globe and with the addition of Austria, Kuwait, and Oman, clinicians will now be able to improve their bedside decision-making with real-time IV infiltration data. Continuous IV site monitoring provides accurate and precise insights to detect infiltrations and extravasations at their earliest stages. ivWatch’s proprietary algorithm detects infiltrations promptly and notifies clinicians of adverse IV therapy events often hours before they are detectable by visual or tactile examination.1

“At ivWatch, we are on a steadfast mission to improve IV safety globally and we are extremely passionate about partnering with likeminded innovators who share that same relentless pursuit to advance patient safety,” said Chuck Egress, Vice President of Business Development and Emerging Markets at ivWatch. “IV infiltrations and extravasations are a major global patient safety concern, and these new partnerships provide increased access to advanced safety solutions to help end complications and improve patient outcomes in IV therapy.”

ivWatch has over 60 patents worldwide and received its first FDA clearance in 2015 for its IV site monitoring system that consists of an ivWatch Patient Monitor and a reusable optical biosensor that uses visible and near-infrared light to continuously measure changes in the optical properties of the tissue near an IV insertion site. In 2020, the company expanded its portfolio of sensor solutions and received FDA clearance for a single-use, miniaturized biosensor that is cleared for all patient age groups, sizes, and skin tones. Both sensors work seamlessly with the intuitive user interface on the Patient Monitor, which issues audible and visual “Check IV” alerts for the clinician to assess the IV site. ivWatch technology performs with high accuracy, intelligence, and low false alarm rates, which is critical to improving patient outcomes.

Read more here.

Recent News

05/31/2023

Apply Now: BLUE KNIGHT™ QuickPitch: Activating for the Future

Recent global disease outbreaks have had devastating impacts, triggering a renewed emphasis on preparation for potential known and unknown health threats. By proactively enhancing preparedness against emerging pathogens, we aim to minimize the scale of future outbreaks, protect vulnerable populations, and ultimately safeguard our health security. To that end, Johnson & Johnson Innovation, together with

05/25/2023

Unintended consequences – FODMAP rich diets and digestive distress

Consumers are increasingly in pursuit of healthier diets, including plant-based diets, Mediterranean style diets and ones high in fiber. Along with these diet changes, though, can come digestive distress from specific dietary elements called FODMAPs (fermentable oligo-, di-, monosaccharides and polyols). FODMAPs can include lactose, found in dairy products; galactans, found in legumes; and fructans,

05/24/2023

Regional Partners Collaborate to Launch Advancing Oncology InnoVAtion QuickFire Challenge

Johnson & Johnson Innovation, in collaboration with Carilion Clinic Innovation, Verge Alliance, and Virginia Tech Corporate Research Center, is proud to launch the Advancing Oncology InnoVAtion QuickFire Challenge. Innovators from around the globe are invited to submit potential solutions aiming to transform patient outcomes in oncology in adult populations with potential applications in pediatric oncology.